Top member reports
No meetings
Consensus community valuation
The consensus valuation is for members only and has been removed from this chart. Click for membership options.
Contributing Members
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
#Shorttermthesis
Added a month ago

Not the highest quality company listed on the ASX, but a short-term (18 months) thesis could play out here, I have 60% confidence in this playing out:

- Recent quarters demonstrate an inflection point where cash flow breakeven can now be sustained (although certainly not consistent), indicating improved operational efficiency and financial stability.

- KKR's acquisition of shares in MedAdvisor on the market suggests some validation of Andrew Smith's thesis (Perenial); emphasising that the company's transformation into a profitable business will make it takeover attractive. 

- Andrew Smith highlights MedAdvisor's attractive valuation metrics, trading at 1.5x revenue compared to peers in the US at five times sales. My opinion is that a takeover offer could potentially be executed at 3x revenue, indicating good upside potential from the current stock price.

Read More
#Quarterly
stale
Added one year ago

I think it's fair to say that MedAdvisor impressed us all when they reported fantastic results. 

Overall revenue was up 89.9% to $44.1 million and their US was up 97.7% to $39.4 million. This resulted in positive operating cashflow of $21M. It’s quite rare to see so much positive cashflow for companies still reporting on a 4C cycle. 

As we can see, the vast majority (89%) of the revenue came from the US business. MedAdvisor acquired the Adheris LLC business from Syneos Health in 2020 for US$34.5 million. The intent of this move was to help the company become the leader of tailored opt-out, direct-to-patient medication adherence programs in the US as well as Australia. Since then, the big revenue has come from marketing campaigns though. And the big boost here was from a Covid awareness program. This is clearly an incredible result and I tip my hat to the team, but doesn’t give us the same visibility of growth to come in the future as a pure Saas player would. 

If you’d like to understand more about the business, Claude Walker wrote up a good piece on a Rich Life after the results. I will be looking at them a little more closely in the future to see what they can achieve.

Read More
#ASX Announcements
stale
Added 3 years ago

MedAdvisor signs 5-year deal with Australian Pharmaceutical Industries (ASX:API) - July 31 2021

Old news now, but noticed there wasn't a straw for this.

Highlights of this deal:

  • 5-year agreement with API, a pharmacy group listed in the ASX known for Priceline Pharmacy stores (among others).
  • Expected revenue is approximately $2.5m over 5 years before transaction and other variable fees (The model is a monthly  recurring  licence  fee).
  • Medadviser will be the framework for the Priceline Covid-19 Vaccination booking (now live) and also a branded version of its mobile application for the Priceline Pharmacy network

That being said I went ahead to book for my vaccination and it was quite satisfying to see it working well as a MDR shareholder, although the UI could use some improvements. It would be great to see more contracts like this come through given the government is extending COVID-19  vaccinations  being  available  in  selected pharmacies. 

 

Read More
#ASX Announcement 21/1/21
stale
Added 3 years ago

December 2020 Quarterly Report and 4C

Key highlights

? Purchased Adheris, LLC creating immediate scale in the USA

? Full year CY20 pro-forma revenue of AUD$56m up 484% on CY19 (AUD:USD $0.70)

? MedAdvisor US (incorporating Adheris) achieved USD$19.3m pro-forma in sales for the December half-year (up 85% on the prior corresponding period (p.c.p) and +40% on the Company’s initial forecast of USD$13.8m pro-forma for the half-year)

? Signed contracts to deliver 50%+ of CY21 Adheris earnout revenue hurdle of USD$32.5m (~AUD$40m) and pipeline is strong

? Recognised revenue of AUD$12.8m for the half-year to 31 December 2020, up AUD$8.3m on the p.c.p. (+188%), and AUD$10.3m for the quarter, including the 6 weeks following the Adheris acquisition on 17 November 2020

? Vaccine product was the highest revenue product for CY20, indicating the significant opportunity for MedAdvisor in this space, as programs drive awareness and dose series completion, critical to ensure patients are adequately vaccinated

? Increased operating cash inflows to AUD$14.2m for the half-year to 31 December, up 196% on the p.c.p.

? MedAdvisor (excl. USA) total revenue of AUD$2.7m for the quarter, up 15.4% on p.c.p

? Raised AUD$42.2m equity from a number of existing shareholders, including HMS, and new institutional investors

? Funded to execute integration and growth plans with AUD$21.2m cash at bank

DISC~I have a small holding

View Attachment

Read More
Valuation of $0.020
stale
Added 4 years ago
Need to see further results but at the moment it spends $2 for every $1 it earns. With 25% revenue increase into pertuity (possible), maintenance of GM @87.5% (has achieved this consistently) and reduction in opex growth to 11% immediately (has never been near this) it only breaks even on an EBITDA basis in year 7.
Read More
Valuation of $0.080
stale
Added 5 years ago
Read More